Stand Up Therapeutics has signed with VectorBuilder for the world’s first gene therapy supply for a paraplegic patient
Stand Up Therapeutics Co., Ltd, located in South Korea, is a gene therapy company for paralyzed patients with spinal cord injury. Stand Up Therapeutics announced on July 21 that it has signed an agreement with VectorBuilder Inc., a global leader in gene delivery solutions, to manufacture a GMP-grade gene delivery system.
VectorBuilder is the world’s largest provider of custom vectors for viral and non-viral gene delivery, operating as a multinational company headquartered in Chicago, USA, with offices in North America, Europe, China, Japan, Korea, Australia and Israel. Currently, more than 80,000 custom vectors are produced each year for many researchers around the world. VectorBuilder has GMP facilities for gene delivery systems and supplies gene therapy products and delivery systems to thousands of institutions worldwide and more than 50,000 customers, including all major pharmaceutical companies and major universities. We provide gene therapy products and delivery systems.
According to Stand Up Therapeutics, through this agreement, VectorBuilder will produce and supply gene therapy products designed by Stand Up Therapeutics in the future. The plan is to dominate the global market.
VectorBuilder Chief Scientist Bruce Lahn said, “VectorBuilder is very interested in Stand Up Therapeutics’ gene therapy for the treatment of paralysis globally. As a world leader in the design and GMP manufacture of gene delivery vectors, I hope this would be a great opportunity for VectorBuilder to provide this product to Stand Up for patients around the world.
Stand Up Therapeutics CEO Dr. Junsang Yoo said, “Stand Up Therapeutics is the only one in the world with the technology that treats paralyzed patients due to spinal cord injury using its own direct cross differentiation (LYH-001). Members of Stand Up Therapeutics will work hard to develop a treatment for patients suffering from paralysis due to traumatic injury. Additionally, “With direct cross-differentiation PIPELINE technology, Stand Up Therapeutics plans to develop treatments for stroke (LYH-002), spinal muscular atrophy (LYH-003), spinal stenosis (LYH-004) and myocardial infarction (LYH-005) in the future.”
Today, there are no approved treatments to prevent or reverse paraplegia, which affects nearly 1 in 50 people worldwide. Stand up Therapeutics is currently conducting Phase I and II clinical trials of LYH-001, a direct cross-differentiation drug. In preclinical trials, LYH-001 successfully treated paraplegia in lumbar spine injury-5 animal model within 40 days.
This year, LYH-001 is to be administered for the treatment of Mr. Lee (34), a patient who suffered an unexpected traffic accident at Gonjiam Tunnel in 2019.
About Stand Up Therapeutics Co., Ltd.
Stand Up Therapeutics Co., Ltd. is a company that develops nerve cell regeneration gene therapy using cutting-edge technology that converts fibroblasts into motor neurons in vivo. Using the direct lineage reprogramming technique, one of the goals of Stand Up Therapeutics is to treat paralyzed patients due to spinal cord and brain injury and to relieve the suffering of mild and severe paralyzed patients. about 1.9% of the world’s population. Stand Up Therapeutics will serve the development of direct reprogramming technology and plans to expand the pipeline through R&D of safer and more effective direct reprogramming methods and gene therapy.
For more information visit: http://stutps.com/